Argenx Se (ARGX) Goodwill & Intangibles (2015 - 2026)
Argenx Se (ARGX) posted quarterly Goodwill & Intangibles of $266.0 million for Q2 2026, down 99.92% year-on-year from $352.3 billion in Q2 2025, and down 35.21% on a QoQ basis from $410.6 million in Q4 2025.
Argenx Se (ARGX) Goodwill & Intangibles (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Goodwill & Intangibles for 12 consecutive years, with $266.0 million the latest figure, recorded in Q2 2026.
- Quarterly Goodwill & Intangibles fell 99.92% year-over-year to $266.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $266.0 million (down 99.92% YoY) and the FY2025 annual result came in at $7.5 billion, up 22.81% from the prior year.
- Goodwill & Intangibles retreated to $266.0 million in Q2 2026 per ARGX's latest filing, from $410.6 million in the prior quarter.
- Over the last five years, Goodwill & Intangibles for ARGX reached as high as $352.3 billion in Q2 2025 and fell as low as $256.8 million in Q4 2023.
- A 5-year average of $39.4 billion and a median of $305.8 million in 2022 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2025 — Goodwill & Intangibles soared 130048.98% — and 2026, when it tumbled 99.92%.
- Year by year, Goodwill & Intangibles stood at $305.8 million in 2022, then declined by 16.03% to $256.8 million in 2023, then gained by 20.06% to $308.3 million in 2024, then jumped by 33.18% to $410.6 million in 2025, then tumbled by 35.21% to $266.0 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $266.0 million, $410.6 million, and $352.3 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266.00 Mn |
| Dec 31, 2025 | 410.57 Mn |
| Jun 30, 2025 | 352.33 Bn |
| Dec 31, 2024 | 308.28 Mn |
| Jun 30, 2024 | 270.71 Mn |
| Dec 31, 2023 | 256.77 Mn |
| Jun 30, 2023 | 319.90 Mn |
| Dec 31, 2022 | 305.80 Mn |
| Jun 30, 2022 | 299.99 Mn |
| Dec 31, 2021 | 303.37 Mn |
| Jun 30, 2021 | 308.33 Mn |
| Dec 31, 2020 | 155.23 Mn |
| Jun 30, 2020 | 46.59 Mn |
| Dec 31, 2019 | 45.70 Mn |
| Jun 30, 2019 | 40.37 Mn |
| Dec 31, 2018 | 63,725.44 |
| Jun 30, 2018 | 11,545.68 |
| Dec 31, 2017 | 142,877.76 |
| Jun 30, 2017 | 17,318.52 |
| Dec 31, 2016 | 24,534.56 |